ARTBIO

Empowering Patient-CentricAdvances In Cancer Care

ARTBIO is redefining cancer care by developing a new class of alpha radioligand therapies (ART) and building the ecosystem that maximizes their potential.

The ARTBIO Approach: Patients at the Core

Radioligand therapy (RLT) has offered a promising new approach for cancer treatment. While beta radioligand therapies are currently more common in clinical practice, alpha radioligand therapies offer potentially significantly better efficacy and safety to patients.

The ARTBIO approach is holistic. It is underpinned by a deep understanding of cancer biology, and the infrastructure needed to effectively design, manufacture, and distribute our therapies.

Our patient-centric approach rests on four pillars:

Differentiated pipeline](/content/our-approach#accordion-wrap/index.html)

\ \ Isotope production: AlphaDirectTM](/content/our-approach#accordion-wrap/index.html)

Ideal isotope: Pb212](/content/our-approach#accordion-wrap/index.html)

ART manufacturing ecosystem](/content/our-approach#accordion-wrap/index.html)

Learn more

A Differentiated Pipeline

We are identifying specific combinations of targets and drug molecules best suited for ART. Our ARTs have high affinity and selectivity in order to effectively kill tumors while sparing healthy tissues.

Currently, ARTBIO has multiple pipeline programs with many more in development: - Our lead program AB001 has entered first in human studies. - Three additional targets (ABA, ABB, and ABC) remain undisclosed.

Programs

Indication

Discovery

Non-Clinical

Phase 1

Phase 2

AB001

212Pb-NG001

Prostate Cancer

Phase 1
ABD

Fully-Owned, In-License

TNBC HNSCC +

Non-Clinical
ABA

212Pb-undisclosed

NSCLC Pancreas +

Non-Clinical
ABC

212Pb-undisclosed

Multiple Solid Tumors

Discovery
HEARTS

Multiple Targets

Multiple Solid Tumors

Discovery

A Team of Pioneers and Innovators in RLT

ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy. Born out of groundbreaking research conducted at the University of Oslo and Norway's Radium Hospital - a research hub with lineage to Marie Curie - ARTBIO's roots in radiology and radiation therapy run deep. Our scientific founders, Roy Larsen and Øyvind Bruland, invented Xofigo (later acquired by Bayer via Algeta), the first-ever metabolically targeted alpha therapy. Both collaborated with the F-Prime team and Radforsk to lay the foundation of ARTBIO in 2021.

Our team is composed of multi-disciplinary experts with decades of experience in advancing complex drugs through all stages of clinical development. We are driven by the power of collective thinking, diversity, and a passion to create smarter solutions together. Finally, we take pride in combining creativity and scientific expertise to address challenges. We value inclusion, collaboration, and fostering strong relationships with our team, partners, health care.

Management Team

Jonathan Freeman, Ph.D

Interim CEO

Margaret Yu, MD

Chief Medical Officer

Philippe Dasse, PharmD

Chief Technical Officer

Amra Demirovic

Chief Human Resources Officer

Nicole Hadas

Chief Legal Officer

Conrad Wüller, MSc

Vice President, Operations

Calvin Lee, MBA

Vice President, Finance

Jordi Vall-llosera Ferran, MSc

Chief Quality Officer

Victor Paulus, PhD

Head and Senior Vice President, Regulatory Affairs

Daniel Rossetto, MSc

Head & SVP, Supply Chain and External Manufacturing

Tanja Aarvak, PhD

Director, Program Management

Gjermund Fjeld Olsen, MSc

VP Engineering & Site Head Oslo

Phil Ruis, PhD

Senior Director, Partnered Discovery and Business Development

Sanjay Sharma, MSc, CRadPhr, PhD

Vice President, CMC Operations and Development

Scott Tria, PhD

VP Medicinal Chemistry

Roy H. Larsen, PhD

Scientific Co-Founder

Øyvind Bruland, MD, PhD

Scientific Co-Founder

Øyvind Bruland, MD, PhD

SAB Chairman and ARTBIO Co-Founder

Roy H. Larsen, PhD

ARTBIO Co-founder

Oliver Sartor, MD

Advisor

Richard P. Baum, MD, PhD

Advisor

Dennis Benjamin, MD, PhD

Advisor

Ted W. Love, MD

Chairman

Jeffrey Tong, PhD

Partner, Third Rock Ventures

Ranjeev (Ronny) Krishana

Susanne Schaffert, PhD

Independent

Alex Pasteur, PhD

Partner, F-Prime Capital

Otello Stampacchia, PhD

Managing Director and Founder, Omega Funds

Maha Katabi, PhD, CFA

General Partner, Sofinnova Investments

Robert Mittendorff, MD, MBA

General Partner, Head of Healthcare, B Capital

Gabe Gelman

Head of Capital Solutions, Baker Brothers Investments

Julie O'Neill, MBA

Independent

Jonathan Freeman, Ph.D

Interim CEO, ARTBIO

Martin Taylor, PhD

Senior Associate, F-Prime (Observer)

Francesco Draetta

Partner, Omega Funds (Observer)

Vyas Ramanan, PhD

Venture Partner, Third Rock Ventures (Observer)

Jack Grimes

Investor, B Capital (Observer)

Chris Carpenter, MD, PhD

Executive Partner, Private Equity, Sofinnova investments (Observer)

Partners

Discovery and Development

Manufacturing

Investors

News and Resources

Learn about the latest ARTBIO news.

Filter By Date

Press ReleasesArticlesPublicationsVideos

Press Releases

ARTBIO Appoints Jonathan Freeman Interim Chief Executive Officer\ \ ARTBIO | July 1, 2026

ARTBIO Implements Voluntary Clinical Hold of ARTISAN Trial for Lead Asset AB001\ \ ARTBIO | April 7, 2026

ARTBIO Announces Dosing of Two Cohorts with AB001 in ARTISAN, a Phase 1 Alpha Radioligand Therapy Clinical Trial for Metastatic Castration Resistant Prostate Cancer\ \ ARTBIO | January 12, 2026

Industry Veteran Jonathan Freeman, Ph.D. Joins ARTBIO As Chief Business Officer\ \ ARTBIO | January 6, 2026

Load More

Join our team

The journey is better together.

Together, we approach challenges head-on and with an open mind. Join our team to help us usher in an entirely new standard of care for cancer patients.

Join us if you are...

passionate about making a difference for cancer patients

a humble achiever

a practical optimist

a consummate learner and un-learner

driven by data and cherish transparency

a compassionate team player

Applying to ARTBIO: Beware of Fraudulent Recruiting Ads and Scams

ARTBIO and other biotech companies have recently noticed an increase in email and social media scams targeting job candidates in our industry. Please note ARTBIO will post any legitimate job openings directly on our website ( www.artbio.com) or through our recruitment partner, Lever. If you wish to verify the legitimacy of a job opening, you may contact us through info@artbio.com and someone from our team will respond directly.

Open positions

Clinical\ \ Senior Clinical Trial Manager\ \ Cambridge, MA

General & Administrative\ \ Office Coordinator (Temp Position, 12 months, 50-60%)\ \ Oslo

Technical Operations & Manufacturing\ \ Associate Director, CMC Development\ \ Oslo

Load More